Zai Lab Limited Share Price & Technical Analysis
ZLAB · $18.61 (-2.57%)
Healthcare / Biotechnology
$18.61
-2.57%
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for g…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-14% return in May, 0% avg return in past 3 year May month.
11% return in 2026, -13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 18% | 3% | 9% | -14% | – | – | – | – | – | – | – | 11% |
| 25 | 7% | 30% | 7% | -17% | -5% | 17% | 5% | -9% | 3% | -23% | -24% | -13% | -22% |
| 24 | -18% | -5% | -23% | -2% | 13% | -5% | 10% | 5% | 24% | 23% | -4% | -11% | 6% |
| 23 | 30% | -16% | -16% | 2% | -6% | -15% | 5% | -15% | -6% | 4% | 10% | 0% | -23% |
| 22 | -21% | 10% | -19% | -14% | -27% | 16% | 16% | 17% | -26% | -35% | 60% | -19% | -40% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.18B
P/E ratio
—
52W high
$44.34
52W low
$15.96
Volume
3,90,060
Beta
0.84
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Zai Lab Limited share price today?
- Zai Lab Limited (ZLAB) last traded around $18.61 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZLAB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZLAB. Download the app for real-time alerts.
- How can I analyze Zai Lab Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.